Angelini Pharma to acquire Catalyst Pharmaceuticals, entering the U.S. Market and consolidating its leadership in Brain Health and Rare Disease

Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for 31.50 USD per share in cash, for a total equity value of approximately 4.1 billion USD (equivalent to 3.5 billion euros) which represents a 21% premium to Catalyst’s unaffected closing share price on April 22, 2026, the last trading day before market signs that the transaction had become public information, as well as a 28% premium to the 30-day volume-weighted average trading price to that unaffected date.

The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026 after the regulatory steps.

This acquisition, announced on May 7 2026, marks a pivotal moment in the Angelini Group’s history, as it strengthens Angelini Pharma's presence in the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases.

Read the press release https://www.angelinipharma.com/news-media/press-releases/angelini-pharma-to-acquire-catalyst-pharmaceuticals/